Global Head, Janssen Business Development
Patrick is Global Head, Janssen Business Development. In this role, Patrick leads the business development organization to identify, execute, integrate and manage global licensing, mergers & acquisitions (M&A), divestiture and out-licensing deals for the Janssen Pharmaceutical Companies of Johnson & Johnson. Patrick assumed this role in April 2015.
Prior to this, Patrick helped design and launch Johnson & Johnson Innovation and was Head of Johnson & Johnson Innovation, London. This Innovation strategy has delivered a robust early-stage portfolio and has helped earn Johnson & Johnson a reputation as a preferred partner with external innovators, entrepreneurs, and academic institutions.
Patrick joined Johnson & Johnson in 1986 at Janssen Pharmaceuticals in Beerse, Belgium. Previously, he was Vice President, New Ventures, Pharmaceuticals, where he led an agile and diverse team who facilitated divestitures, established strategic collaborations, and identified investments that provided Janssen with access to external innovation and early product flow. Patrick also served as Vice President, M&A, where he facilitated strategic collaborations and acquisitions including Crucell, Elan, and Cougar Biotechnology, and established spin-out companies, including Movetis. Patrick has provided expertise on most of the major M&A deals in the biotech, specialty pharmaceutical and large capital space, and assessed various risk sharing and funding arrangements with Clinical Research Organizations, private equity groups, and government institutions.
Patrick studied bioengineering at the University of Leuven, Flanders, Belgium.